A Study of LY2835219 in Healthy Participants
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 1/9/2019 |
| Start Date: | February 2014 |
| End Date: | August 2014 |
Effect of Food on the Pharmacokinetics of LY2835219 in Healthy Subjects
Participants in this study will receive 3 single oral doses of LY2835219 at least 14 days
apart. One dose will be given with a standard meal, one dose with a high-fat meal and one
dose without food. The study will evaluate the effects of the standard and high-fat meals on
how much drug gets into the bloodstream. Side effects will be documented. This study is
approximately 43 days, not including screening. Screening is required within 28 days prior to
the start of the study.
apart. One dose will be given with a standard meal, one dose with a high-fat meal and one
dose without food. The study will evaluate the effects of the standard and high-fat meals on
how much drug gets into the bloodstream. Side effects will be documented. This study is
approximately 43 days, not including screening. Screening is required within 28 days prior to
the start of the study.
Inclusion Criteria:
- Healthy sterile males or surgically sterile or postmenopausal females
- Have a body mass index (BMI) of 18 to 32 kilogram per meter square (kg/m^2),
inclusive, at screening
- Are able to eat a high-fat, high-calorie meal
Exclusion Criteria:
- Participated in a clinical trial involving investigational product within 30 days
- Abnormal blood pressure
- Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the
investigator, increases the risks associated with participating in the study
- Have donated blood of more than 500 milliliter (mL) within the last month
- Show evidence of human immunodeficiency virus, hepatitis B or hepatitis C
We found this trial at
1
site
Click here to add this to my saved trials
